key: cord-0682862-mj16c559 authors: Bansal, Shruti; Jonsson, Colleen B.; Taylor, Shannon L.; Figueroa, Juan Manuel; Dugour, Andrea Vanesa; Palacios, Carlos; César Vega, Julio title: Iota-carrageenan and Xylitol inhibit SARS-CoV-2 in cell culture date: 2020-08-21 journal: bioRxiv DOI: 10.1101/2020.08.19.225854 sha: 00363c053d290ced5cec482aaaf84f39ae037481 doc_id: 682862 cord_uid: mj16c559 COVID-19 (coronavirus disease 2019) is a pandemic caused by SARS-CoV-2 (severe acute respiratory syndrome-coronavirus 2) infection affecting millions of persons around the world. There is an urgent unmet need to provide an easy-to-produce, affordable medicine to prevent transmission and provide early treatment for this disease. The nasal cavity and the rhinopharynx are the sites of initial replication of SARS-CoV-2. Therefore, a nasal spray may be a suitable dosage form for this purpose. The main objective of our study was to test the antiviral action of three candidate nasal spray formulations against SARS-CoV-2. We have found that iota-carrageenan in concentrations as low as 6 µg/ mL inhibits SARS-CoV-2 infection in Vero cell cultures. The concentrations found to be active in vitro against SARS-CoV-2 may be easily achieved by the application of nasal sprays already marketed in several countries. Xylitol at a concentration of 5 % m/V has proved to be viricidal on its own and the association with iota-carrageenan may be beneficial, as well. SARS-CoV-2 is a single stranded positive sense RNA virus responsible for COVID-19. COVID-35 19 has become one of the worst pandemics of our time counting more than 12.232,700 confirmed cases 36 and more than 554,000 deaths worldwide by July 10 th , 2020 [1] . In most cases, COVID-19 manifests 37 itself clinically with flu-like symptoms as a mild or uncomplicated illness, eventually resolving 38 spontaneously. However, 15% of patients develop severe pneumonia that requires hospitalization and 39 oxygen support, and 5% of them need admission to an intensive care unit (ICU). More than half of this 40 patients may die [2] . Even children can be affected although with milder symptoms than adults and can be 41 transmitters of the disease. [3] . There are no adequate therapeutic or preventive medicines available, so 42 effective therapeutic approaches are urgently needed to reduce the spread of the virus and its death toll. 43 seed stock was prepared in T175 flasks of Vero E6 cells using a multiplicity of infection (MOI) of 0.1. 95 Each flask was harvested on day two post-infection and supernatant was centrifuged twice at 220 x g for 96 15 minutes to remove cellular debris. Titer of virus stock was determined by plaque assay on Vero E6 97 cells. Center. Composition of different formulations is depicted in Tables 1 and 2 . Samples 1, 2 and 3 were 103 diluted at stock concentrations of 1200 µg/mL, 120 µg/mL, 12 µg/mL and 1.2 µg/mL using samples P1, 104 P2 and P3 respectively as diluents. To determine antiviral efficacy of formulations by titer reduction 105 assay, sample formulations were used at a final iota-carrageenan concentration of 600 µg/mL; 60 µg/mL, 106 6 µg/mL and 0.6 µg/mL. Equivalent concentration of placebos (samples P1, P2 and P3) was used for titer 107 reduction assay as controls. 108 109 Vero E6 cells were seeded in 12-well plates at density of 2.5x10 5 /well and grown overnight at 120 37 0 C under 5%CO2. Next day, cells were washed with PBS (pH 7.2), followed by addition of equivalent 121 amount of c-MEM with reduced FBS (2%) and sample/placebo formulations. Formulations were 122 incubated with cells for 2 hr, after which the supernatant was removed. Cells were infected with 2.5x10 4 123 pfu (MOI=0.1) of virus for 1 hr at 37C, 5%CO2 with rocking at 15 min intervals. After incubation wells 124 were washed with DPBS, and sample/placebo formulations were added at same concentrations. After 125 incubation for 2 days, well contents were collected. For titer reduction, wells with no treatment (only 126 virus) and cells only were included. Virus titer was determined by performing a TCID50 assay using MTT 127 to measure cell viability. Virus endpoint titer was determined using the Reed-Muench formula and 128 expressed as log TCID50/mL. Residual virus titer from sample/placebo formulation treated wells was 129 plotted against virus titer from untreated wells. 130 To examine the antiviral effects of iota-carrageenan on SARS-CoV-2, three sample formulations 134 were developed and tested. Each of the three sample formulations were tested in a dose dependent manner 135 based on the concentration of iota-carrageenan and ranged from 600 µg/mL to 0 µg/mL. SARS-CoV-2 136 samples treated with 600 µg/mL and 60 µg/mL of sample formulation 1 were reduced > 3.75 Log when 137 Underlying data reported in tables S3A and S3B as supporting information. A comparison of all three samples tested indicate that iota-carrageenan (600 µg/mL, 60 µg/mL, 196 and 6 µg/mL) in samples 1 and 2 are effective at inhibiting SARS-CoV-2 (Table 3) . Sample 3, which 197 contained xylitol, was the most effective and demonstrated an antiviral effect at all concentrations tested 198 (Table 3) . 199 We are starting multicenter randomized controlled trials to evaluate the efficacy of iota-243 carrageenan nasal sprays in health care staff assisting COVID-19 patients and in patients suffering from 244 COVID 19 and other persons in close contact with them. However, it must be stressed that this and other 245 similar nasal sprays are on the market and their safety profile is remarkable. The current COVID-19 246 emergency warrants the urgent development of potential strategies to protect people even if more robust 247 data on antiviral therapies is yet to come. COVID 19: 263 Dashboard by the Characteristics of and Important Lessons from the Coronavirus Disease 266 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases from the Chinese 267 Center for Disease Control and Prevention COVID-19 in children: the link in the transmission chain. The Lancet 270 Infectious Diseases SARS-CoV-2 Viral Load in Upper 272 Respiratory Specimens of Infected Patients Nasal-Swab Testing Misses Patients 275 with Low SARS-CoV-2 Viral Loads Correlation Between Relative Nasopharyngeal Virus 279 RNA Load and Lymphocyte Count Disease Severity in Patients with COVID-19 Viral dynamics in mild and severe cases of The Lancet Infectious Diseases Antiviral Potential of Algae Polysaccharides 285 Isolated from Marine Sources: A Review. BioMed Research International Carrageenan is a potent 288 inhibitor of papillomavirus infection Antiviral activity of 291 carrageenan on hepatitis A virus replication in cell culture Carrageenan is a potent inhibitor of rhinovirus infection Specific inhibitory effect of κ-carrageenan polysaccharide 297 on swine pandemic 2009 H1N1 influenza virus Interference in dengue virus adsorption and uncoating by 300 carrageenans Efficacy and 302 safety of an antiviral Iota-Carrageenan nasal spray: A randomized, double-blind, placebo-303 controlled exploratory study in volunteers with early symptoms of the common cold Carrageenan nasal spray in virus confirmed common cold: Individual patient data analysis of two 307 randomized controlled trials Carrageenan nasal spray in patients with common cold: A randomized controlled trial Carrageenan Is a Potent Inhibitor of Influenza A Virus Infection Safety assessment of 342 inhaled xylitol in mice and healthy volunteers Nasal Drug Delivery in Humans Topical Applications and the Mucosa Dosimetry of nasal 348 uptake of water-soluble and reactive gases: A first study of interhuman variability Anatomical and Histological Factors Affecting Intranasal Drug and Vaccine 351 Intranasal Drug Delivery: How, Why and What for? A novel fluorescent sensor 355 protein for detecting changes in airway surface liquid glucose concentration Anatomic and physiologic considerations in sinusitis Practical strategies for a safe and effective delivery of aerosolized medications to patients 360 with COVID-19 The authors thank Augusto Pich Otero and his team at Laboratorio Pablo Cassará S.R.L. 259 (Argentina) for the supply of the sterile formulations for this in vitro study. 260 261 formulation after delivering one 100-µL of a 1.2 mg/mL iota-carrageenan solution in each nostril, the 220 immediate concentration of iota-carrageenan in the nasal cavity would be 600 µg/mL, coinciding with 221 the highest concentration tested in vitro and capable of reducing virus yield to the LOD in our assay. 222Furthermore, considering that even 1/100 of this concentration is still active in vitro and that iota-223 carrageenan may stay for 4 hours [19] in the nasal cavity, there is a reasonable chance that this nasal spray 224 may significantly help in the prevention and early treatment of COVID-19. Expected concentrations of 225 iota-carrageenan in the nasal cavity will be even higher, if we consider a nasal formulation containing 1.